Skip to main content
300 Collins St Melbourne
hello@pivot.net
Login
Signup
Main navigation
About
Team
News
Contact
Research & Development
Innovation Engine
Therapeutic Focus
Development Strategy
Pipeline
RMC-4630
Mutant RAS
SOS1
RMC-5552
Investors
Careers
News
Publication / Presentation
January 12, 2020
The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial.
Read more
Publication / Presentation
January 12, 2020
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC
Read more
Publication / Presentation
January 11, 2020
The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial.
Read more
Publication / Presentation
November 20, 2019
Translating Frontier Oncology Targets To Outsmart Cancer Using Multiple Allosteric Approaches
Read more
Publication / Presentation
October 29, 2019
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo
Read more
Publication / Presentation
October 28, 2019
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo
Read more
Publication / Presentation
October 28, 2019
4EBP3 mRNA as a Biomarker of Therapeutic Response to Treatment with mTORC1 Inhibitors
Read more
Publication / Presentation
September 19, 2019
Translating Frontier Oncology Targets to Outsmart Cancer
Read more
Publication / Presentation
September 9, 2019
Industry Leading RAS Drug Discovery Engine
Read more
Publication / Presentation
September 9, 2019
Discovery of Small Molecule Inhibitors of the Oncogenic, GTP-Bound (ON) Form of KRASG12C and KRASG13C
Read more
